Loading…
Lyell Immunopharma, Inc. is projected to rise to $16.90 by 2027, a +13% move from its current price of $15.01. LYEL is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 14 | $14.25 | $15.01 | $15.80 | -0.03% |
| Jul 15 | $13.95 | $15.00 | $16.13 | -0.06% |
| Jul 16 | $13.72 | $15.00 | $16.39 | -0.08% |
| Jul 17 | $13.53 | $14.99 | $16.62 | -0.11% |
| Jul 18 | $13.36 | $14.99 | $16.81 | -0.14% |
| Jul 19 | $13.21 | $14.98 | $16.99 | -0.17% |
| Jul 20 | $13.08 | $14.98 | $17.16 | -0.20% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $13.08 | $14.98 | $17.16 | -0.20% |
| Week 2 | $12.34 | $14.95 | $18.12 | -0.39% |
| Week 3 | $11.79 | $14.92 | $18.88 | -0.59% |
| Week 4 | $11.35 | $14.89 | $19.54 | -0.79% |
| Week 5 | $10.97 | $14.86 | $20.14 | -0.98% |
| Week 6 | $10.63 | $14.83 | $20.69 | -1.18% |
| Week 7 | $10.33 | $14.80 | $21.21 | -1.37% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Lyell Immunopharma, Inc. is a healthcare company focused on clinical-stage cell therapies. It develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
The lead product candidate is rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development, in pivotal PiNACLE trial in the 3L+ setting and in a Phase 1/2 clinical trial in the 2L setting. A second pivotal PiNACLE-H2H trial is a Phase 3 head-to-head CAR T cell therapy randomized controlled trial of ronde-cel for LBCL in the 2L setting for the treatment of large B-cell lymphoma. Lyell also has LYL273, a GCC-targeted CAR T-cell product candidate enhanced with CD19 CAR expression and controlled cytokine release designed to improve CAR T-cell expansion, immune cell infiltration, and cancer cell killing in the hostile solid tumor microenvironment, which is in Phase 1 clinical trial for the treatment of refractory metastatic colorectal cancer.
The company develops therapies using approaches such as c-Jun overexpression and NR4A3 gene knockout to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; and CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Lyell Immunopharma, Inc. (LYEL) is publicly tracked with a current price of $15.91 and a market capitalization of $371.25M. It holds a rank of 3306 in market capitalization among listed peers. The stock’s near-term price dynamics sit in a neutral territory, reflecting a cautious stance from traders and investors.
A major floor 40.5% below — a decisive break under it would weaken the trend.
The nearest floor, 22.7% below — buyers have tended to step in here.
The nearest ceiling, 15.5% above — a clean break opens room to run.
A major ceiling 70.8% above — clearing it would confirm fresh momentum.
Key LYEL support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of LYEL market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $15.11 | Sell | $14.92 | Buy |
| MA 10 | $14.10 | Buy | $14.41 | Buy |
| MA 20 | $13.48 | Buy | $14.17 | Buy |
| MA 50 | $15.73 | Sell | $15.75 | Sell |
| MA 100 | $19.12 | Sell | $17.85 | Sell |
| MA 200 | $20.83 | Sell | $18.80 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 53.38 | Neutral |
| Stoch RSI (14) | 81.81 | Sell |
| CCI (20) | 105.73 | Buy |
| Williams %R (14) | -20.93 | Info |
| MACD (12,26,9) | 0.51 | Buy |
| ROC (12) | 18.84 | Buy |
| Bollinger %B (20,2) | 0.83 | Neutral |
| Stochastic %K (14) | 79.07 | Neutral |
| TRIX (15) | -0.64 | Sell |
| Awesome (5,34) | 1.01 | Buy |
| Ultimate (7,14,28) | 57.80 | Neutral |
| Momentum (10) | 2.52 | Buy |
| Aroon Osc (25) | 24.00 | Buy |
| Hull MA (9) | 15.83 | Sell |
| ADX (14) | 20.45 | Buy |
| ATR (14) | 0.68 | Info |
The sentiment is NEUTRAL with RSI 14 at 60. The stock trades near the SMA50 of $16.15 and below the SMA200 of $20.80, suggesting a mixed intermediate trend. Support is cited at $11.61 and resistance at $17.46, framing a 30-day range from $11.01 to $23.00.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $11.61 | $15.01 | $21.36 | 0% | Neutral | |
| $12.35 | $16.90 | $24.97 | +13% | Neutral | |
| $11.92 | $17.28 | $27.17 | +15% | Neutral | |
| $9.23 | $14.06 | $23.17 | -6% | Neutral | |
| $9.10 | $14.50 | $24.85 | -3% | Neutral | |
| $10.58 | $17.58 | $31.16 | +17% | Neutral | |
| $11.02 | $19.05 | $34.79 | +27% | Bullish | |
| $12.83 | $23.04 | $43.21 | +53% | Bullish | |
| $12.64 | $23.55 | $45.27 | +57% | Bullish | |
| $10.74 | $20.75 | $40.79 | +38% | Bullish | |
| $14.38 | $31.97 | $68.92 | +113% | Bullish | |
| $19.28 | $42.84 | $98.54 | +185% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $11.61 | $15.01 | $18.41 | +0.00% |
| August 2026 | $11.94 | $14.43 | $18.14 | -3.89% |
| September 2026 | $11.94 | $14.63 | $18.77 | +1.40% |
| October 2026 | $12.67 | $15.71 | $20.50 | +7.37% |
| November 2026 | $12.72 | $15.93 | $21.08 | +1.42% |
| December 2026 | $12.61 | $15.94 | $21.36 | +0.04% |
Click any year to see its month-by-month LYEL forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, LYEL could reach as high as $21.36, with a base case around $15.01 and support toward $11.61 — roughly 0% from $15.01. A consolidation phase looks the most probable path here.
Expect LYEL to range from $12.35 to $24.97 through 2027. The $16.90 average target implies a +13% move from current prices. That is up +13% on the projected 2026 average. Price action looks broadly range-bound.
The LYEL price prediction for 2028 points to an average of $17.28 (low $11.92, high $27.17) — a potential gain of +15% on today's $15.01. A consolidation phase looks the most probable path here.
In 2029, LYEL is projected to trade between $9.23 and $23.17, averaging $14.06 — a potential decline of -6% from today's $15.01. That is -19% versus the projected 2028 average. Price action looks broadly range-bound.
Lyell Immunopharma, Inc.'s 2030 outlook centres on $14.50, within a $9.10 to $24.85 range. That is up +3% on the projected 2029 average. That marks a -3% change versus current levels. A consolidation phase looks the most probable path here.
By 2031, LYEL could reach as high as $31.16, with a base case around $17.58 and support toward $10.58 — roughly +17% from $15.01. Price action looks broadly range-bound.
Expect LYEL to range from $11.02 to $34.79 through 2032. The $19.05 average target implies a +27% move from current prices. That is up +8% on the projected 2031 average. Buyers look set to stay in control over this stretch.
The LYEL price prediction for 2033 points to an average of $23.04 (low $12.83, high $43.21) — a potential gain of +53% on today's $15.01. Momentum favours further upside here.
In 2034, LYEL is projected to trade between $12.64 and $45.27, averaging $23.55 — a potential gain of +57% from today's $15.01. That is up +2% on the projected 2033 average. Buyers look set to stay in control over this stretch.
Lyell Immunopharma, Inc.'s 2035 outlook centres on $20.75, within a $10.74 to $40.79 range. That is -12% versus the projected 2034 average. That marks a +38% change versus current levels. Momentum favours further upside here.
By 2040, LYEL could reach as high as $68.92, with a base case around $31.97 and support toward $14.38 — roughly +113% from $15.01. Buyers look set to stay in control over this stretch.
Expect LYEL to range from $19.28 to $98.54 through 2050. The $42.84 average target implies a +185% move from current prices. That is up +34% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in LYEL today (≈ 66.622252 LYEL) could be worth
$2,854.3
+$1,854.3 (+185%) by 2050 · US Dollar
Based on the average projected LYEL price of $42.84 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in LYELwould be worth at today's price.
$1,000 invested in LYEL on Jul 10, 2025 (≈ 102.354141 LYEL) would be worth
$1,536.34
+$536.34 (+53.6%) today · 1.54× · US Dollar
Based on a LYEL entry price of $9.77 vs. today's $15.01.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $14.05 | $1,068.33 | +6.8% |
| 1 month ago | $13.22 | $1,135.4 | +13.5% |
| 3 months ago | $22.39 | $670.39 | -33.0% |
| 6 months ago | $23.77 | $631.47 | -36.9% |
| 1 year ago | $9.77 | $1,536.34 | +53.6% |
| All time (5.0y) ago | $333.4 | $45.02 | -95.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our LYEL forecast.
Our base-case forecast reaches $30.00 around 2040.
Implied market cap at $30.00: $700.02M
The multi-year forecast shows a path of variable returns, with the 2026 average price at $15.91 and a 2026 low of $11.61 and high of $22.89. For 2027 the average is $17.96 with a 12.9 ROI, and 2028 an average of $18.11 with a 13.8 ROI. The 2029 forecast drops to an average of $14.66 (ROI -7.9), followed by 2030 at $15.38 (ROI -3.3).
The outlook improves later, with 2031 at $19.08 (ROI 19.9), 2032 at $21.02 (ROI 32.1), 2033 at $25.42 (ROI 59.8), 2034 at $25.70 (ROI 61.5), and 2035 at $22.40 (ROI 40.8). The long horizon turns strongly bullish in 2040 with an average of $35.23 (ROI 121.4) and in 2050 an average of $48.17 (ROI 202.8). These figures illustrate a wide range of outcomes, with notable upside in the later years but with uncertainty and variability across the forecast.
Tap a question to reveal the answer.
Avg $15.38; Min $9.50; Max $26.70; ROI -3.3; Sentiment NEUTRAL.
Forecasts show mixed results: positive ROIs in 2027 (12.9), 2028 (13.8), 2032 (32.1), 2033 (59.8), 2034 (61.5), 2040 (121.4), and 2050 (202.8), but negative ROIs in 2029 (-7.9) and 2030 (-3.3). These are estimates and not guarantees.
Yes. The forecast max for 2034 is $50.18.
Avg $35.23; Max $77.35; Min $15.85; ROI 121.4; Sentiment BULLISH.
Current price $15.91; Market cap $371.25M.
Lyell Immunopharma, Inc. Community Discussion
0Share your Lyell Immunopharma, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.